Aurobindo Pharma, an India-based drugmaker, received FDA approval for Didanosine (chewable) Tablets of strengths 100 mg, 150 mg and 200 mg. Didanosine is a key component of the antiretroviral (ARV) regimens in various part of the world.
This product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief. With this approval, the ARV product portfolio of Aurobindo has increased to 17.
Didanosine helps prevent HIV from reproducing. It is used in combination with other antiretroviral agents for the treatment of HIV-1 indication. Didanosine is the version of VIDEX, an anti-HIV medication manufactured by Bristol-Myers Squibb.